Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTG Wall + EMD for Intrabony Periodontal Defects
NCT07233733Completed
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Open-label, single-arm trial of enamel matrix derivative in periodontitis. Primary endpoints: Clinical Attachment Level Gain at 6 months, Recession Interproximal at 6 months and 3 more. Started Jun 2024; status: completed.
02
Drugs
enamel matrix derivative
03
Conditions
periodontitis
Beyond the preview
Go deeper on NCT07233733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233733.